Neurovascular Intervention

One focus of stem cell-based therapy for stroke is using mesenchymal stem cells (MSCs). MSCs are a type of stem cell found in many different tissues in the body and can potentially differentiate into other cell types, including neurons. MSCs have been studied for their potential to treat neurological disorders, including ischemic brain injury, acute ischemic stroke, hemorrhagic stroke, and chronic stroke. They have shown promising results in preclinical and early clinical studies.

Preclinical studies have proven the efficacy of stem cell therapy for ischemic stroke using IA transplantation. Although clinical studies have demonstrated the safety of IA transplantation, efficacy is yet to be established. Multiple confounding variables, including optimal timing, cell dose, cell type, stroke type, stroke severity, and patient age, would explain the discrepancy in treatment efficacy between preclinical and clinical studies. Therefore, optimization of IA stem cell transplantation is necessary, and then further experiments in basic research are needed to fill these discrepancies and confirm the optimal conditions for IA stem cell transplantation.

A 2022 study crunched how much exactly treatment would cost per stroke patient. Short-term it’s around $149,180, with the price to reach $249,780 per stroke patient in the long-term. Luckily, stroke can be prevented and can be treated – if patients get medical help quickly – because the longer treatment is delayed, the more damage the stroke can cause.

On postoperative day 14, the patient had a transit ischemic attack and imaging showed acute occlusion due to thrombus in the stent and in the distal part of the ICA. Mechanical thrombectomy was performed and good recanalization was achieved, but postoperative cerebral infarction was observed and the patient was transferred to other hospital with modified Rankin Scale 2.

A new study shows that deep brain stimulation could be beneficial for stroke patients undergoing rehabilitation, with improvements in motor function and impairment.

“In neurology, we often say that ‘time is brain’,” said Shyam Prabhakaran (University of Chicago, Chicago, USA), senior author on the study, which has been published in the Journal of the American Medical Association (JAMA). “For every 15 minutes that pass without treatment, prior research shows there is a steady decrease in the chances of good outcomes for stroke patients. Getting to the right hospital quickly can be lifesaving.”

Early use of antiplatelet treatment after mechanical thrombectomy (MT) for acute ischemic stroke is associated with better functional outcomes without safety concerns, according to a study presented at the annual meeting of the Society of NeuroInterventional Surgery, held from July 31 to Aug 4 in San Diego. Hepzibha Alexander, M.D., from Ascension Providence Hospital in Southfield, Michigan, and colleagues evaluated the safety and functional outcomes of antiplatelet use within 24 hours following MT. Analysis included prospective data for 190 consecutive patients who underwent MT for acute ischemic stroke (2016 to 2020).

Our study indicates that low preoperative PNI is significantly associated with a higher incidence of ischemic stroke in patients undergoing non-cardiac surgery. Preoperative PNI, as a preoperative nutritional status evaluation index, is an independent risk factor useful to predict perioperative ischemic stroke risk, which could be used as an intervenable preoperative clinical biochemical index to reduce the incidence of perioperative ischemic stroke.

Brainomix’s e-Stroke imaging technology uses artificial intelligence (AI) to automatically process CT and MRI scans and alert doctors in real-time about those patients who would benefit most from mechanical thrombectomy (MT), a life-changing treatment which can reduce disability and prevent or limit long-term care needs in patients with the most severe strokes due to blockage of a large blood vessel supplying the brain. Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.

On August 3, 2023, the APEX TRA SYSTEM™ radial artery access guidance system, independently developed by NeuroVita, a subsidiary of Sinomed, has been approved for marketing by the National Drug Administration of the People's Republic of China (NMPA).
In October 2022, the Chinese Expert Consensus on Transradial Artery Access for Neurological Intervention was released, recommending that transradial access has higher safety, and patients do not need to be bedridden after the procedure, which can significantly improve patient comfort, reduce bedridden complications and nursing workload, shorten hospitalization time, and reduce hospitalization costs, so it is being more and more widely used in the field of coronary interventional diagnosis and treatment. However, the lack of specialized instruments is an important factor limiting the development of transradial artery approach neurointervention. At present, although the procedure can be completed by using conventional instruments to establish access via the radial artery, it is time-consuming to establish the access, the system support is insufficient, and the catheter of the access is easy to be broken during the procedure, etc. There is an urgent need to develop a specialized instrument for transradial nerve intervention. Therefore, this transradial coaxial system will further simplify the surgical operation, improve the safety and stability of transradial treatment, shorten the treatment time of transradial surgery, and reduce the incidence of complications.

This study found a significant increase in intracranial bleeding with daily low-dose aspirin but no significant reduction of ischemic stroke. These findings may have particular relevance to older individuals prone to developing intracranial bleeding after head trauma.

Ischemic strokes are relatively frequent in Morocco. Their management generates an important cost, which is influenced by several factors such as severity of the disease and the duration of hospitalization. This cost can be decreased by rationalizing the expenses and acting on various risk factors of ischemic strokes.

The surface of this coated flow-diverter dense mesh stent independently developed and manufactured by NeuroVita adopts a unique ultra-thin anti-thrombotic coating design, which has a high bonding strength with the substrate and possesses the advantages of hydrophilicity and anti-thrombosis, and it is the first dense mesh stent with an anti-thrombotic coating design in China at present. In the present clinical trial, only a single antiplatelet drug was used in some of the cases after the operation, and we are full of anticipation for the results of the followup.

The Pounce™ Thrombectomy System was designed for use in time-critical situations. It’s a “grab and go” percutaneous mechanical thrombectomy solution that empowers physicians to strike quickly, capturing and removing clot from the peripheral arterial vasculature without requiring any capital equipment for operation.

The Hmong people are an ethnic group of clans primarily from mountainous areas in Laos, China, Vietnam and Thailand. Many fought alongside the United States during the Vietnam War. Persecution from that alliance forced thousands of Hmong to flee Southeast Asia in the mid- to late 1970s, with many coming to the U.S. as refugees. The U.S. Hmong population now hovers at an estimated 368,609, according to 2021 census data.

Treatment of MeVO patients with Q catheters resulted in optimal angiographic and clinical outcomes. Although angiographic results were similar between primary and secondary MeVOs, the former had less severe presenting NIHSS and better outcomes at 90 days than the latter.

Our method provides a promising step towards the development of more effective and biocompatible endovascular devices. The CD31 domain 1 coating prevented the pathologic local reaction at the site of stent implantation and promoted faster and more effective device integration. Further studies are necessary to investigate the efficacy and safety of CD31 domain 1 coatings on a larger scale, as well as their long-term durability and potential clinical applications.

Sexual intercourse should be considered an important trigger for IS. Clinicians should be aware that IS associated with sexual intercourse is not subjective but may be a warning sign of multiple etiologies and mechanisms.

Anticoagulants did not reduce ATE risk among ambulatory patients on systemic anticancer therapy and were associated with increased bleeding. Based on the current data, anticoagulants have a limited role in ATE prevention in this population as a whole.

Medical treatment is the mainstay of most cases of ICAD, whether asymptomatic or symptomatic. However, for patients who have failed medical treatment, endovascular revascularization can be performed with a low risk in most subgroups. Patients with hemodynamic compromise and large vessel emboli presentation appear to have the most potential benefit for intracranial artery stenting. The primary long-term risk for these patients post-stenting is in-stent re-stenosis. The use of DCB and DES has demonstrated lower re-stenosis rates, but shown mixed results regarding periprocedural complications. Currently, there are no FDA-approved DCB or DES devices for ICAD. The use of stenting as a rescue therapy in LVO thrombectomy has also shown promising early results. The investigation of this option in failed revascularization during thrombectomy may be beneficial to patients with AIS.

Elon Musk’s Neuralink isn’t the only company making progress on connecting people’s brains to computers. In April and May, surgeons at West Virginia University placed thin strips of a cellophane-like material on the brains of three patients. Made by New York-based startup Precision Neuroscience, the thumbnail-sized strips are designed to conform to the surface of the brain without damaging its delicate tissue.

The measured expenditures varied considerably among these studies with a global average cost from €610-€220,822.45. Given the great variability in the costs in different studies, we can conclude that we need to define a common system for assessing the costs of strokes. Possible limitations are related to clinical choices exposed to decision rules that trigger decisions alerts within stroke events in a clinical setting. This flowchart is based on the guidelines for acute ischemic stroke treatment but may not be applicable to all institutions.

Introduction In 2017, 1.5 million people were diagnosed with stroke, 9 million were living with stroke and 0.4 million died because of stroke in 32 European countries. We estimate the economic burden of stroke across these countries in 2017. Patients and methods In a population-based cost analysis, we evaluated the cost of stroke. We estimated overall health and social care costs from expenditure on care in the primary, outpatient, emergency, inpatient and nursing/residential care settings, and pharmaceuticals.